Whitney Wharton1, Felicia C Goldstein1, Liping Zhao2, Kyle Steenland3, Allan I Levey1, Ihab Hajjar2,4. 1. Department of Neurology, School of Public Health, Emory University, Atlanta, Georgia. 2. Department of Medicine, School of Medicine, School of Public Health, Emory University, Atlanta, Georgia. 3. Department of Environmental and Occupational Health, School of Public Health, Emory University, Atlanta, Georgia. 4. Department of Biostatistics and Bioinformatics, School of Public Health, Emory University, Atlanta, Georgia.
Abstract
OBJECTIVES: To assess the effect of modulation of the renin-angiotensin system (RAS) on conversion to Alzheimer's disease (AD) and cognitive decline in people with mild cognitive impairment (MCI) and the effect of the permeability of the blood-brain barrier (BBB) and race on the potential relationship between the RAS and AD. DESIGN: Analysis of data from AD centers funded by the National Alzheimer's Coordinating Center, National Institute on Aging. SETTING: Alzheimer's Disease Centers. PARTICIPANTS: Individuals receiving antihypertensive medications who had MCI at baseline and had cognitive assessments on at least two follow-up visits (N = 784; mean age 75 l 48/% male). MEASUREMENTS: Conversion to AD and cognitive and functional decline. RESULTS: Four hundred eighty-eight participants were receiving RAS-acting antihypertensive medications. RAS-acting medication users were less likely to convert to AD (33% vs 40%; P = .04) and had slower decline on the Clinical Dementia Rating Sum of Boxes (CDR-SOB, P = .005) and Digit Span Forward (P = .02) than nonusers. BBB-crossing RAS-acting medications were associated with slower cognitive decline on the CDR-SOB, (P = .009), the Mini-Mental State Examination (MMSE), (P = .001), and the Boston Naming test (P = .002). RAS-acting medications were associated with cognitive benefits more in African Americans than in Caucasians (MMSE, P = .05; category fluency, P = .04; Digit Span Backward, P = .03). CONCLUSION: RAS-acting medication users were less likely to convert to AD. BBB permeability may produce additional cognitive benefit, and African Americans may benefit more from RAS modulation than Caucasians. Results highlight the need for trials investigating RAS modulation during prodromal disease stages.
OBJECTIVES: To assess the effect of modulation of the renin-angiotensin system (RAS) on conversion to Alzheimer's disease (AD) and cognitive decline in people with mild cognitive impairment (MCI) and the effect of the permeability of the blood-brain barrier (BBB) and race on the potential relationship between the RAS and AD. DESIGN: Analysis of data from AD centers funded by the National Alzheimer's Coordinating Center, National Institute on Aging. SETTING:Alzheimer's Disease Centers. PARTICIPANTS: Individuals receiving antihypertensive medications who had MCI at baseline and had cognitive assessments on at least two follow-up visits (N = 784; mean age 75 l 48/% male). MEASUREMENTS: Conversion to AD and cognitive and functional decline. RESULTS: Four hundred eighty-eight participants were receiving RAS-acting antihypertensive medications. RAS-acting medication users were less likely to convert to AD (33% vs 40%; P = .04) and had slower decline on the Clinical Dementia Rating Sum of Boxes (CDR-SOB, P = .005) and Digit Span Forward (P = .02) than nonusers. BBB-crossing RAS-acting medications were associated with slower cognitive decline on the CDR-SOB, (P = .009), the Mini-Mental State Examination (MMSE), (P = .001), and the Boston Naming test (P = .002). RAS-acting medications were associated with cognitive benefits more in African Americans than in Caucasians (MMSE, P = .05; category fluency, P = .04; Digit Span Backward, P = .03). CONCLUSION: RAS-acting medication users were less likely to convert to AD. BBB permeability may produce additional cognitive benefit, and African Americans may benefit more from RAS modulation than Caucasians. Results highlight the need for trials investigating RAS modulation during prodromal disease stages.
Authors: E Savaskan; C Hock; G Olivieri; S Bruttel; C Rosenberg; C Hulette; F Müller-Spahn Journal: Neurobiol Aging Date: 2001 Jul-Aug Impact factor: 4.673
Authors: M Kivipelto; E L Helkala; T Hänninen; M P Laakso; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: Neurology Date: 2001-06-26 Impact factor: 9.910
Authors: Sevil Yasar; Jin Xia; Wenliang Yao; Curt D Furberg; Qian-Li Xue; Carla I Mercado; Annette L Fitzpatrick; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Jeff D Williamson; Steven T DeKosky; Michelle C Carlson Journal: Neurology Date: 2013-08-02 Impact factor: 9.910
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Rónán O'Caoimh; Liam Healy; Yang Gao; Anton Svendrovski; David M Kerins; Joseph Eustace; Patrick Gavin Kehoe; Gordon Guyatt; D William Molloy Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Whitney Wharton; Felicia C Goldstein; Malú G Tansey; Alexandra L Brown; Sonum D Tharwani; Danielle D Verble; Amarallys Cintron; Patrick G Kehoe Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: C Barrett Bowling; Richard Sloane; Carl Pieper; Alison Luciano; Barry R Davis; Lara M Simpson; Paula T Einhorn; Suzanne Oparil; Paul Muntner Journal: J Am Geriatr Soc Date: 2020-06-05 Impact factor: 5.562
Authors: Jean K Ho; Frank Moriarty; Jennifer J Manly; Eric B Larson; Denis A Evans; Kumar B Rajan; Elizabeth M Hudak; Lamiaa Hassan; Enwu Liu; Nobuyuki Sato; Naoyuki Hasebe; Danielle Laurin; Pierre-Hugues Carmichael; Daniel A Nation Journal: Hypertension Date: 2021-06-21 Impact factor: 9.897